Anti-PRMT7 Antibody, clone 7G11

Evaluated by Western Blotting in NIH/3T3 cell lysate.

Western Blotting Analysis: 1 µg/mL of this antibody detected PRMT7 in 10 µg of NIH/3T3 cell lysate.

Anti-PRMT7, clone 7G11 Antibody, Cat. No. MABE357, is a highly specific mouse monoclonal antibody that targets PRMT7 and has been tested in Western Blotting.

Research Category
Epigenetics & Nuclear Function

Western Blotting Analysis: 1 µg/mL from a representative lot detected PRMT7 in 10 µg of HeLa cell lysate.

Clone 7G1 was raised against the full-length 692-a.a. spliced isoform (UniProt Q9NVM4-1), reactivity toward the other three spliced isoforms reported by UniProt is possible, but has not been confirmed.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Protein arginine N-methyltransferase 7 (EC 2.1.1.321; UniProt Q9NVM4; also known as Histone-arginine N-methyltransferase PRMT7, [Myelin basic protein]-arginine N-methyltransferase PRMT7) is encoded by the PRMT7 (also known as KIAA1933) gene (Gene ID 54496) in human. Mammalian protein arginine methyltransferases (PRMTs) catalyze the methylation of arginine residues on histone and non-histone proteins. PRMTs are divided into three types based on their mode of activity. Type I PRMTs (PRMT1–4, PRMT6, and PRMT8) transfer up to two methyl groups on the same terminal guanidino nitrogen of arginine to form ω-NG-monomethylarginine (MMA) and ω-NG,NG-asymmetric dimethylarginine (ADMA) residues. Type II PRMTs (PRMT5 and PRMT9) transfer methyl groups on different terminal guanidino nitrogens to form ΜΜΑ and ω-NG,N′G-symmetric dimethylarginine (SDMA) residues, while type III PRMT7 transfers only one single methyl group to form MMA residues. PRMT7 is involved in mediating cellular resistance or sensitivity to cytotoxic agents, as well as in regulating male germline imprinted gene via interaction with CCCTC-binding factor-like protein (CTCFL). PRMT7 is also reported to inhibit neuronal cell differentiation through the repression of MLL4-dependent gene expression, implicating a role in a stem cell population maintenance and cancer development. PRMT7 knockdown is shown to decrease breast cancer cell invasion in vitro and metastasis in vivo, while PRMT7 overexpression is shown to enhance the invasiveness of a non-aggressive breast cancer cell line by inducing the expression of MMP9. Similar to PRMT9, but unlike other PRMTs, PRMT7 contains a duplicated methyltransferase domain (a.a. 14-345 and 358-684), with the N-terminal MTase acting as a funtional AdoMet-binding domain and the C-terminal MTase domain serving a pseudodimer function, mimicking the homodimer formation of other PRMTs needed for subtrate processing. Deletion of either domain in PRMT7 abolishes its activity.

~78.5 kDa observed. 78.46/62.12/73.15/63.81 kDa (isoform 1/2/3/4) calculated. Uncharacterized bands may be observed in some lysate(s).

GST-tagged full-length recombinant human PRMT7.

Concentration: Please refer to lot specific datasheet.

Format: Purified

Protein G purified.

Purified mouse IgG2b in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

Stable for 1 year at 2-8°C from date of receipt.